Fumiyuki Shirai

Wako, 3510198, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

HTD1265 Disrupts GimC-Dependent Cellular Processes in Saccharomyces cerevisiae.

HTD1265 Disrupts GimC-Dependent Cellular Processes in Saccharomyces cerevisiae.

Journal: Pathogens (Basel, Switzerland)

Published: January 16, 2026

A Novel PROTAC G9a/GLP Degrader that Inhibits, Similar to G9a siRNA, the Migration of MCF-7 Breast-Cancer Cells without Affecting Proliferation.

A Novel PROTAC G9a/GLP Degrader that Inhibits, Similar to G9a siRNA, the Migration of MCF-7 Breast-Cancer Cells without Affecting Proliferation.

Journal: Journal of medicinal chemistry

Published: August 31, 2025

Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease.

Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease.

Journal: European journal of medicinal chemistry

Published: January 27, 2025

Cell-type specific, inducible and acute degradation of targeted protein in mice by two degron systems.

Cell-type specific, inducible and acute degradation of targeted protein in mice by two degron systems.

Journal: Nature communications

Published: May 15, 2024

Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment.

Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment.

Journal: Bioorganic & medicinal chemistry letters

Published: April 24, 2024

Reduction of H3K9 methylation by G9a inhibitors improves the development of mouse SCNT embryos.

Reduction of H3K9 methylation by G9a inhibitors improves the development of mouse SCNT embryos.

Journal: Stem cell reports

Published: December 01, 2023

BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.

BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.

Journal: Cancer letters

Published: September 27, 2023

An ex vivo screening using mouse brain mitochondria identified seco-cycline D as an inhibitor of mitochondrial permeability transition pore.

An ex vivo screening using mouse brain mitochondria identified seco-cycline D as an inhibitor of mitochondrial permeability transition pore.

Journal: Biochemical and biophysical research communications

Published: July 07, 2023

Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents.

Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents.

Journal: Journal of medicinal chemistry

Published: March 08, 2023

APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.

APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.

Journal: British journal of cancer

Published: December 11, 2022

A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression.

A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression.

Journal: Nature communications

Published: April 13, 2022

Novel tankyrase inhibitors suppress TDP-43 aggregate formation.

Novel tankyrase inhibitors suppress TDP-43 aggregate formation.

Journal: Biochemical and biophysical research communications

Published: December 10, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026